{"title":"建立5剂不含白蛋白的三联病毒疫苗,以减少给药过程中的损失","authors":"S. Assumpção, M. Freire, E. Caride, C. Crespo","doi":"10.35259/isi.2022_52264","DOIUrl":null,"url":null,"abstract":"the established approval limits. Conclusion: The results demonstrate that only the 5-dose presentation, with a 67% reduction in filling volume, replacement of the current vial model and recalculation of vaccine component concentrations, maintains the productive capacity with the number of doses per batch produced, in the same time and lyophilization cycle currently used.","PeriodicalId":8089,"journal":{"name":"Annals of the symposium: vaccines, biopharmaceuticals, in vitro diagnosis, management, other related themes","volume":"44 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Establishment 5 doses presentation of the triple viral vaccine without albumin to reduce loss during administration\",\"authors\":\"S. Assumpção, M. Freire, E. Caride, C. Crespo\",\"doi\":\"10.35259/isi.2022_52264\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"the established approval limits. Conclusion: The results demonstrate that only the 5-dose presentation, with a 67% reduction in filling volume, replacement of the current vial model and recalculation of vaccine component concentrations, maintains the productive capacity with the number of doses per batch produced, in the same time and lyophilization cycle currently used.\",\"PeriodicalId\":8089,\"journal\":{\"name\":\"Annals of the symposium: vaccines, biopharmaceuticals, in vitro diagnosis, management, other related themes\",\"volume\":\"44 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of the symposium: vaccines, biopharmaceuticals, in vitro diagnosis, management, other related themes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35259/isi.2022_52264\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of the symposium: vaccines, biopharmaceuticals, in vitro diagnosis, management, other related themes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35259/isi.2022_52264","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Establishment 5 doses presentation of the triple viral vaccine without albumin to reduce loss during administration
the established approval limits. Conclusion: The results demonstrate that only the 5-dose presentation, with a 67% reduction in filling volume, replacement of the current vial model and recalculation of vaccine component concentrations, maintains the productive capacity with the number of doses per batch produced, in the same time and lyophilization cycle currently used.